Clinical Trials: Page
-
As new drugs take hold, Lilly ramps up R&D spend
Lilly spent nearly a quarter of its revenue on R&D in 2015 - the third highest figure in the industry.
By Ned Pagliarulo • April 28, 2016 -
Major study shows no increased suicide risk from smoking cessation drugs
Pfizer's Chantix and GlaxoSmithKline's Zyban have carried black-box warnings for neuropsychiatric side effects.
By Nicole Gray • April 25, 2016 -
Explore the Trendline➔
Getty Images
TrendlineRadiopharmaceuticals
A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.
By BioPharma Dive staff -
FDA
Despite efforts of advocates, FDA panel votes against Sarepta's Duchenne drug
Many in the patient community had pegged their hopes on Sarepta's eteplirsen, after two other drugs for the condition were turned down by the FDA.
By Ned Pagliarulo • April 25, 2016 -
Proton pump inhibitors linked to serious kidney diseases in study
The study compared PPIs like AstraZeneca's Nexium to drugs known as H2 blockers.
By Nicole Gray • April 25, 2016 -
Deep Dive
Inside the development of Venclexta, AbbVie's new leukemia drug
Venclexta should help bolster AbbVie's oncology portfolio as it works to offset the threat of generic competition to its best-seller Humira.
By Ned Pagliarulo • April 22, 2016 -
Bluebird Bio gene therapy sees encouraging early results in treatment of rare brain disease
The MA-based biotech hopes to prove its therapy is more effective than allogeneic stem-cell transplants.
By Ned Pagliarulo • April 21, 2016 -
Armed with genetic data, UK biotech revisits abandoned Roche cholesterol drug
Several other large pharma companies have dropped similar drugs after studies failed to prove any cardiovascular benefits.
By Nicole Gray • April 20, 2016 -
NIH suspends work at two facilities, including T-cell research
One of the facilities, a National Cancer Institute lab, was manufacturing T-cell therapies in collaboration with Kite Pharma.
By Ned Pagliarulo • April 19, 2016 -
Bristol-Myers' Opdivo shows promise in head, neck cancers
The new data extend a string of positive results for the immunotherapy.
By Ned Pagliarulo • April 19, 2016 -
With new studies, Boehringer and Lilly to pit diabetes drug against heart failure
Jardiance is the first diabetes treatment proven to reduce the risk of cardiovascular disease.
By Ned Pagliarulo • April 19, 2016 -
AbbVie's experimental hep c combo proves highly effective across genotypes
The combination treatment would also offer improved convenience as a once-daily regimen, compared to the company's multipill Viekira Pak.
By Nicole Gray • April 18, 2016 -
EASL 2016: Merck's 'no patient left behind' approach to hepatitis C
The company's hep c med Zepatier faces an uphill battle as it competes against Gilead's dominant treatments, leading Merck to look at typically untreated patient populations.
By Nicole Gray • April 18, 2016 -
Bristol-Myers' Opdivo gets boost from long-term survival data
More than a third of patients with advanced melanoma who received Opdivo survived past five years.
By Ned Pagliarulo • April 18, 2016 -
Review of NCI facilities halts patient enrollment in Kite T-cell studies
Separately, the biotech announced three patients in an early stage trial of one of its T-cell treatments had continued to show durable responses against solid tumors.
By Ned Pagliarulo • April 17, 2016 -
FDA
Most cancer drug labels don't include patient experiences: study
As a comparison, researchers found nearly 25% of other drugs included patient-reported outcomes information.
By Nicole Gray • April 15, 2016 -
After Alzheimer's drug passes safety review, AstraZeneca and Lilly push into Phase 3
Despite the many drug development failures in the Alzheimer's space, several companies are hopeful so-called BACE inhibitors can slow progression of the disease.
By Ned Pagliarulo • April 8, 2016 -
In phase 3 collaboration, Merck and Pfizer testing PDL1/TKI combo
The trial aims to test the efficacy of the combo against renal cell carcinoma, compared to Pfizer's older drug Sutent.
By Ned Pagliarulo • April 5, 2016 -
ACC 2016: Boehringer's Pradaxa 'antidote' passes real-world test
Praxbind, a reversal agent for the blood thinner Pradaxa, has been a key feature in Boehringer's new marketing campaign.
By Nicole Gray • April 4, 2016 -
Study shows no clinical benefit from Lilly's failed cholesterol drug
Lilly had previously discontinued a 12,000 person trial for the once-heralded CETP inhibitor evacetrapib due to lack of efficacy.
By Ned Pagliarulo • April 4, 2016 -
Montgomery County Planning Commission
GSK gene therapy for rare immune disorder wins EMA approval
Children born with the disorder have almost no ability to fight off everyday infections due to a compromised immune system.
By Ned Pagliarulo • April 3, 2016 -
ACC 2016: Novartis' Entresto reduces risk of hospitalization in HF patients
The data will likely help Novartis as it builds out recent pay-for-performance deals with Aetna and Cigna, two major insurers.
By Nicole Gray • April 3, 2016 -
Lilly's arthritis drug baricitinib notches another success
The drug will have significant competition however, as a number of companies are also lining up new rheumatoid arthritis treatments.
By Nicole Gray • April 1, 2016 -
FDA panel says benefits outweigh risks for Acadia's Parkinson's drug
The advisory committee voted 12-2 in favor of the Parkinson's disease psychosis drug, setting the stage for a FDA decision May 1.
By Ned Pagliarulo • March 29, 2016 -
Theranos blood testing inconsistent with other labs, study shows
Compared to testing by LabCorp and Quest Diagnostics, Theranos' technology was 1.6 times more likely to yield abnormal results.
By Nicole Gray • March 29, 2016 -
New phase 2 data boosts prospects for Alder's migraine drug
The company hopes to stay abreast of competing companies, such as Amgen and Lilly, which are developing drugs using the same mechanism as Alder's ALD403.
By Ned Pagliarulo • March 28, 2016
Previous
